Literature DB >> 2146455

Cutaneous phototoxic occurrences in patients receiving Photofrin.

T J Dougherty1, M T Cooper, T S Mang.   

Abstract

Incidence of cutaneous phototoxic reactions induced by intravenous injection of Photofrin polyporphyrin was assessed in a series of 180 patients (266 injections) undergoing photodynamic therapy (PDT) at Roswell Park Cancer Institute during the period 1986-1989. In addition to the usual verbal questions regarding phototoxic reactions solicited at follow-up, forty-two patients in this group also responded to a written questionnaire designed to solicit answers to specific questions. Photofrin doses ranged from 0.5 to 2.0 mg/kg. Overall, 20-40% of patients reported some type of phototoxic response.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2146455     DOI： 10.1002/lsm.1900100514

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN： 0196-8092            Impact factor:   4.025


  37 in total

1.  Advantages of salvage photodynamic therapy using talaporfin sodium for local failure after chemoradiotherapy or radiotherapy for esophageal cancer.

Authors:  Tatsunori Minamide; Yusuke Yoda; Keisuke Hori; Kensuke Shinmura; Yasuhiro Oono; Hiroaki Ikematsu; Tomonori Yano
Journal:  Surg Endosc       Date:  2019-05-28       Impact factor: 4.584

2.  A bioactivatable self-quenched nanogel for targeted photodynamic therapy.

Authors:  Huacheng He; Anna-Liisa Nieminen; Peisheng Xu
Journal:  Biomater Sci       Date:  2019-10-02       Impact factor: 6.843

Review 3.  Antibody-targeted polymer-bound drugs.

Authors:  B Ríhová
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

4.  Photodynamic Activity of Liposomal Photosensitizers via Energy Transfer from Antenna Molecules to [60]Fullerene.

Authors:  Atsushi Ikeda; Motofusa Akiyama; Takuya Ogawa; Tatsuo Takeya
Journal:  ACS Med Chem Lett       Date:  2010-04-08       Impact factor: 4.345

Review 5.  Successful cutaneous delivery of the photosensitizer silicon phthalocyanine 4 for photodynamic therapy.

Authors:  M Lam; A H Hsia; Y Liu; M Guo; A R Swick; J C Berlin; T S McCormick; M E Kenney; N L Oleinick; K D Cooper; E D Baron
Journal:  Clin Exp Dermatol       Date:  2011-05-30       Impact factor: 3.470

6.  Panendoscopy as a screening procedure for simultaneous primary tumors in head and neck cancer.

Authors:  I J Dhooge; M De Vos; F W Albers; P B Van Cauwenberge
Journal:  Eur Arch Otorhinolaryngol       Date:  1996       Impact factor: 2.503

7.  Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study.

Authors:  J Regula; A J MacRobert; A Gorchein; G A Buonaccorsi; S M Thorpe; G M Spencer; A R Hatfield; S G Bown
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

8.  Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs.

Authors:  J Hongrapipat; P Kopecková; S Prakongpan; J Kopecek
Journal:  Int J Pharm       Date:  2007-09-22       Impact factor: 5.875

Review 9.  Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies.

Authors:  Janine D Miller; Elma D Baron; Heather Scull; Andrew Hsia; Jeffrey C Berlin; Thomas McCormick; Valdir Colussi; Malcolm E Kenney; Kevin D Cooper; Nancy L Oleinick
Journal:  Toxicol Appl Pharmacol       Date:  2007-02-15       Impact factor: 4.219

10.  Photodynamic activity of BAM-SiPc, an unsymmetrical bisamino silicon(IV) phthalocyanine, in tumour-bearing nude mice.

Authors:  S C H Leung; P-C Lo; D K P Ng; W-K Liu; K-P Fung; W-P Fong
Journal:  Br J Pharmacol       Date:  2008-03-10       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.